Cisplatin injected into lung tumors for stage 4 lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether injecting the chemotherapy drug cisplatin directly into lung tumors can help people with stage 4 lung cancer. The treatment is given during a procedure called EBUS, which uses a scope to reach the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage 4 non-small cell lung cancer (NSCLC), or your cancer has spread during treatment.
- You are able to perform daily activities with some help (ECOG score 0-2).
- You have a tumor that can be reached with the EBUS scope.
- Your blood counts and liver and kidney function are within acceptable levels.
- You are not pregnant or breastfeeding, and you have not had chemotherapy in the last 14 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to give the chemotherapy drug cisplatin—as a dry powder you inhale—for people with stage IV non-small cell lung cancer who have not yet started treatment. The goal is to see if this inhaled form is safe and effective when added to standard immunotherapy or chemotherapy.
This trial checks whether adding cisplatin to standard chemotherapy after surgery helps women with high-risk early-stage breast cancer lower the chance of the cancer coming back. You would be followed to see how well treatment works and whether it is tolerated.
This trial studies an anti-cancer gel that delivers cisplatin directly into a head and neck tumor with a single injection. It mainly checks safety and side effects, and also looks for early signs that the tumor responds in people whose cancer is progressing or no longer responds to standard treatment.
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
This trial tests a combination of two chemotherapy drugs, cisplatin and gemcitabine, for people with certain rare cancers that no longer respond to a type of immunotherapy called PD-1 inhibitors. The goal is to see how well this treatment works and what side effects it may cause.
This trial tests a new drug combination for people with advanced non-squamous non-small cell lung cancer who have not had treatment before. It compares the new drug with a standard immunotherapy, both given with chemotherapy, to see which is more effective.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.